Amador Bioscience, a US-based global translational sciences and clinical pharmacology CRO, announced on Friday that it has named Dr Meina Liang as its new chief technology officer.
In the new role, the company said that Dr Liang is to head the strategy to establish cutting-edge bioanalysis technologies and capabilities, improving the company's global-standard services to biopharmaceutical companies.
Dr Liang has served as executive director and global head of Integrated Bioanalysis at AstraZeneca. She has held various scientist and leadership positions with increasing responsibilities at Berlex Bioscience/Schering AG, Abgenix/Amgen, and Medimmune.
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Enable Biosciences names new chief financial officer
Cadenza Bio names new director
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation